With diabetes on a constant rise, the number is expected to go higher than 640 million by 2040. For this, it is of prime importance to overcome challenges regarding costs and delays in image grading and pave way for timely detection for rapid treatment of diabetic retinopathy (DR).

Several automated systems of image grading for DR screening are CE marked some of which are RetMarker (Critical Health), iGradingM (Digital Healthcare), iDx-DR (IDx), and EyeArt (Eyenuk). many of these were assessed for the National Health Service in a study.

Of these, the FDA cleared the IDx-DR system screening solution in 2018 by the FDA. A sensitivity of 87%, specificity of 90%, and imageability of 96% were depicted. However, this system is was approved for use with only the Topcon non-mydriatic camera and it may not be applicable in places in which other cameras are used. on the contrary, the EyeArt system is a multi camera-based, meaning it can function with many camera systems. It had a sensitivity of 91.3% and specificity of 91.1%. It is being researched if patients being tested for disease severity and prognosis should be exposed to peripheral retinal DR lesions.

If this is to be incorporated in the healthcare system, Dr. Sadda, the president and chief scientific officer at the University of California says, that patients could undergo eye screenings and the images could be accessed from the cloud, then on the basis of urgency, the referral recommendations could be generated.